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Abstract
Multidrug-resistance and extensive drug-resistance pose a serious threat to tuberculosis management in Portugal. The country has high
TB incidence rates in comparison with other European Union countries, with the Lisbon Health Region being one of the most affected.
In the present study we have analysed a convenience sample of 3025 Mycobacterium tuberculosis clinical isolates, recovered over a 6-year
period (2001–2006) in the Lisbon Health Region, regarding drug-resistance both to ﬁrst-line and second-line drugs. Moreover, 100 of
these isolates were also genotyped by 12-loci Mycobacterial Interspersed Repetitive Unit – Variable Number of Tandem Repeats
(MIRU-VNTR) analysis. We have compared each year and observed the existence of 22 different resistance proﬁles, with MDR-TB rates
ranging between 9.9% and 15.2% and XDR-TB rates, relative to the number of MDR-TB isolates, between 44.3% and 66.1% (excluding
1 year here considered as an outlier). A steady increase in the fraction of MDR-TB isolates resistant to all ﬁrst-line drugs was also
noticed. The genotyping analysis of MDR-TB isolates revealed six clusters, of which three (Lisboa3, Lisboa4 and Q1) were related to
XDR-TB. Our results show that active transmission of MDR- and XDR-TB is taking place and that the high prevalence of observed
XDR-TB is due to the continued transmission of particular genetic clusters. Enforcement of the implementation of genotyping in diag-
nostic routines would lead to early detection of resistant cases.
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Introduction
The worldwide control of tuberculosis (TB) infection and
transmission may be severely hampered by the recurrent
development of resistance to antibacillary drugs. Multidrug-
resistance (MDR) and extensive drug-resistance (XDR) con-
stitute a special and more serious case of resistance because
it renders ineffective the most efﬁcient ﬁrst- and second-line
drug therapies, respectively.
Although TB cases resistant to second-line drugs were
widely known, growing awareness of the widespread and
growing rates in industrialized nations highlighted the neces-
sity to recognize and classify this old problem [1]. According
to the latest World Health Organization report, at least one
XDR-TB case has been described in 58 countries [2]. Other
reports also highlight XDR-TB as a very serious global public
health crisis. The survival rates associated with XDR-TB are
low compared with MDR-TB or susceptible TB. Population
studies performed in Russia, South Korea and Peru indicated
survival rates of 48%, 54% and 60%, respectively, among
HIV-negative patients [3–5].
The tuberculosis situation in Portugal is worrisome. The
incidence rate is high, taking into account the incidence rates
of the other European Union members and the recent
reports by some of us concerning the high prevalence of
MDR-TB and XDR-TB in the Lisbon Health Region.
Genotyping of clinical isolates would allow a better identi-
ﬁcation of transmission chains. The main genetic clusters
present in the region were already identiﬁed and the major-
ity described more than 10 years ago. Such isolates appar-
ently continue to circulate in the region and have inclusively
spread to other regions in the country without noticeable
limitations [6,7].
The National Institute of Health Dr. Ricardo Jorge (INSA-
RJ) laboratory has, over the years, collected and analysed a
high number of TB clinical isolates, mainly from the Lisbon
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Health Region. In the present report, we analyse the
prevalence of resistant isolates, including MDR- and XDR-
TB, over a 6-year period (2001–2006).
Methods
Clinical isolates
We have analysed the data records of all clinical isolates sent
for identiﬁcation and drug susceptibility tests at the INSA-RJ,
Portugal’s national TB Reference Laboratory. For the entire
study, a convenience sample of 3025 isolates were selected
from our tuberculosis database. The selection of these iso-
lates was based on: complete information concerning drug
susceptibility testing; and isolation in the Lisbon Health
Region. Isolates with no Mycobacterium tuberculosis complex
identiﬁcation were discarded and duplicate isolates were
removed from the dataset. These criteria allowed the selec-
tion of 283 isolates from 2001, 741 from 2002, 667 from
2003, 547 from 2004, 442 from 2005 and 345 from 2006.
Antimicrobial susceptibility testing
All isolates were tested for susceptibility to ﬁrst-line drugs (iso-
niazid, rifampicin, streptomycin, ethambutol and pyrazinamide)
by the BACTEC 960 MGIT or BACTEC 460 (Becton-
Dickinson) method according to the manufacturer’s indica-
tions. Isolates resistant to isoniazid and rifampicin were consid-
ered MDR-TB and tested for second-line drug susceptibility.
Second-line drug susceptibility testing was performed by
the BACTEC 460 system for capreomycin (1.25 lg/m), ami-
kacin (1.0 lg/m), kanamycin (5.0 lg/m), ciproﬂoxacin (1.0 lg/
m), oﬂoxacin (2.0 lg/m), ethionamide (5.0 lg/m) and para-
amino salicylic acid (4.0 lg/m), according to Pfyffer et al. [8].
MDR-TB isolates resistant to, at least, a ﬂuoroquinolone
(oﬂoxacin or ciproﬂoxacin) and a second-line injectable drug
(capreomycin, kanamycin and amikacin) were considered
XDR-TB isolates.
Mycobacterial interspersed repetitive unit – variable num-
ber of tandem repeats (MIRU-VNTR) genotyping
One hundred isolates (28 from 2004, 48 from 2005 and 24
from 2006) were genotyped by the automated 12 loci MIRU-
VNTR technique as described by Supply et al. [9].
Results
For this study, the records of a total of 3025 clinical isolates
were analysed. The analysis of these isolates allows us to
assess the TB situation regarding drug resistance among all
isolates tested at the TB National Reference Laboratory
from Portugal’s National Institute of Health Dr. Ricardo
Jorge. This convenience sample may also provide a general
picture of the prevalence of MDR-TB and XDR-TB in the
Lisbon Health Region.
We started by analysing the isolates resistant to ﬁrst-line
antibacillary drugs. Overall, we found 22 different resistant
proﬁles in isolates resistant to one or more ﬁrst-line drugs
distributed throughout the years (2001–2006). Eight proﬁles
met the criteria for MDR-TB, with 2003 registering the high-
est number of MDR-TB cases (82) (Table 1).
The analysis of the susceptibility to second-line drugs
yielded 26 different resistant patterns, 15 of which corre-
sponded to XDR-TB isolates (Table 2). From 2001 to 2006,
14 (2006) to 47 (2003) XDR-TB cases were detected in this
study.
The trend seen in MDR-TB and XDR-TB cannot be
clearly evaluated because the varying number of clinical sam-
ples received by the laboratory for testing may act as a con-
founding factor in such analysis. Nevertheless, considering
the years 2002–2005, an increase in the MDR-TB may have
occurred because in 2005 the MDR-TB cases accounted for
15.3%, an increase of approximately 4% compared with the
three previous years (Table 3). Also, the percentage of
MDR-TB isolates with resistance to all ﬁrst-line drugs
appears to show a steady increase from 2001/2002 to 2006,
varying between 25.9% in 2002 and 52.9% in 2006. Consider-
ing the XDR-TB rate, and taking into account the year 2006
as an outlier given the low number of tested strains, we
TABLE 1. First-line resistance proﬁles found among the
analysed isolates in each year
Resistance proﬁle
No. of clinical isolates studied per year
2001 2002 2003 2004 2005 2006
Pan-susceptible 220 548 503 424 331 268
E 0 0 0 0 0 2
ES 0 0 0 0 0 1
I 4 26 6 12 14 5
IES 0 0 0 0 1 0
IESP 0 0 0 2 0 0
IP 2 2 1 2 1 1
IR 2 10 3 0 3 3
IRE 0 0 0 0 1 1
IREP 3 4 0 2 9 3
IRES 4 2 6 4 2 0
IRESP 11 21 32 24 30 18
IRP 1 7 7 4 4 1
IRS 7 6 7 4 5 1
IRSP 12 31 27 19 13 7
IS 5 13 16 16 9 10
ISP 0 2 1 0 1 0
P 0 0 0 0 5 0
R 0 3 2 3 0 1
RP 0 0 1 0 0 0
RS 0 1 0 0 0 0
S 12 65 54 31 12 23
SP 0 0 1 0 1 0
Total 283 741 667 547 442 345
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verify that it varied between 44.3% (2002) and 66.1% (2004),
with a mean value of 54.3%.
Twelve-loci MIRU-VNTR genotyping analysis was imple-
mented in 2004, and for that reason it was not possible to
assess the genetic clusters circulating in the previous years.
Genotyping data were available for 100 of the selected
MDR-TB isolates from 2004 to 2006. A MIRU-VNTR den-
drogram of the genotyped isolates was produced for each
year. Genetic clusters were deﬁned as a group of two or
more isolates exhibiting the same MIRU-VNTR pattern. A
clear predominance of Lisboa family strains was veriﬁed
between 2004 and 2006. Six clusters were identiﬁed, with
three belonging to the Lisboa family (Lisboa3, Lisboa4 and
Lisboa10) (Fig. 1). Lisboa3, Lisboa4 and Q1 clusters were
related to XDR-TB, with Lisboa3 having the highest number
of XDR-TB cases (Table 4).
Discussion
Portugal is a country with a considerable TB incidence, tak-
ing into account the other EU countries. The high number of
XDR-TB cases and rates in an area of 14 572 km2 (Lisbon,
Setu´bal and Santare´m districts) are of concern to those who
have to manage this problematic situation.
In a previous publication we have pointed to two possible
explanations for the high prevalence of XDR-TB in Portugal:
the non-containment of Lisboa Family strains and the high
ﬂuoroquinolone prescription rate [6,10,11]. Additionally, the
use of the WHO-recommended standard treatment regimen
for MDR-TB suspected cases with unavailability of the ﬁrst-
line drug susceptibility test results may potentiate this situa-
tion [12]. This treatment regimen includes a 6-month initial
phase with kanamycin, ethionamide, a ﬂuoroquinolone, pyra-
zinamide and ethambutol. In a previous study, we have
shown that 92% of the MDR-TB isolates were also resistant
to ethionamide, mostly due to cross-resistance between iso-
niazid and ethionamide, and that 79.4% of the same MDR-TB
isolates were also resistant to ethambutol and/or pyrazina-
mide [6]. In the present study, that proportion ranged from
77.5% to 93.0% and resistance to ethionamide among all
tested isolates was seen to range from 80.0% to 94.1%. Con-
sequently, the use of the MDR-TB standard treatment regi-
men in the Portuguese setting does not provide the patient
with the necessary active drugs and may lead to resistance
to second-line injectable drugs and/or ﬂuoroquinolones and
hence to XDR-TB development.
The results presented here show that, in accordance with
previous studies by some of us, XDR-TB is not only a cur-
rent problem that must be addressed, but is the result of a
continued circulation of MDR-TB clones detected in the
1990s [7]. The main clusters detected have been shown to
maintain their prevalence over the 3-year period (where
TABLE 2. Second-line resistance proﬁles found among the
analysed isolates in each year
Resistance proﬁles
No. of clinical isolates studied per
year
2001 2002 2003 2004 2005 2006
Pan-susceptiblea 2 6 7 7 12 3
CAP AMK CIP OFX ETH 0 0 0 1 0 1
CAP AMK ETH PAS 0 0 1 0 0 0
CAP AMK KAN CIP ETH 1 1 0 0 0 0
CAP AMK KAN CIP ETH PAS 0 3 0 0 0 0
CAP AMK KAN CIP OFX ETH 4 5 10 14 11 3
CAP AMK KAN CIP OFX ETH PAS 0 0 1 5 7 2
CAP AMK KAN CIP OFX PAS 0 0 0 0 1 1
CAP AMK KAN ETH 0 1 4 1 2 0
CAP AMK KAN ETH PAS 0 0 1 0 0 0
CAP AMK KAN OFX 0 0 1 0 0 0
CAP CIP ETH 1 0 1 0 0 0
CAP CIP ETH PAS 0 1 0 0 0 0
CAP CIP OFX ETH 2 3 3 1 1 0
CAP ETH 0 0 0 0 1 0
CAP ETH PAS 0 0 0 0 1 0
CAP KAN CIP OFX ETH 4 6 20 8 7 3
CAP KAN CIP OFX ETH PAS 0 5 7 1 6 2
CAP OFX ETH 0 0 0 1 0 0
CIP ETH 0 2 1 1 1 0
CIP OFX 0 1 0 1 0 0
CIP OFX ETH 5 4 5 2 4 1
CIP OFX ETH PAS 0 4 1 0 0 0
ETH 9 35 17 10 17 2
KAN CIP OFX ETH 6 6 4 5 2 1
KAN CIP OFX ETH PAS 0 5 1 1 0 1
ND 249 653 581 488 369 325
OFX 0 0 1 0 0 0
Total 283 741 667 547 442 345
aSusceptible to all second-line tested drugs.
TABLE 3. Number and percentage of resistant, MDR- and XDR-TB isolates, distributed by each year (2001–2006)
Resistance
No. of isolates (%)
2001 2002 2003 2004 2005 2006
Total 283 741 667 547 442 345
Resistanta 63 (22.3) 193 (26.0) 164 (24.6) 123 (22.5) 111 (25.1) 77 (22.3)
MDR-TBb 40 (14.1) 81 (10.9) 82 (12.3) 57 (10.4) 67 (15.2) 34 (9.9)
XDR-TBc 18 (52.9) 35 (44.3) 47 (57.3) 37 (66.1) 34 (50.7) 14 (73.7)
aIsolates resistant to one or more antibacillary drugs.
bIsolates resistant to at least isoniazid and rifampicin.
cXDR-TB rate expressed as the fraction of the tested MDR-TB isolates with resistance to at least one second-line injectable drug and a ﬂuoroquinolone.
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genotyping was available) in the MDR-TB/XDR-TB scenario
of the Lisbon Health Region.
The largest cluster of XDR-TB in the world, in South
Africa, belongs to the KZN family of TB strains, described in
1996 and at the time pan-susceptible or resistant to ﬁrst-line
drugs only [13]. In Portugal, the situation is similar; the
Lisboa family, which was identiﬁed in 1996, was already
strongly associated with MDR-TB at that period and now is
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FIG. 1. MIRU-VNTR dendrograms of MDR-TB isolates recovered in the years 2004 (a), 2005 (b) and 2006 (c). First-Line DST: I, isoniazid; R, rif-
ampicin; S, streptomycin; E, ethambutol; P, pyrazinamide.
TABLE 4. Distribution of the MDR-TB genotyped isolates per cluster per year and number of XDR-TB isolates in each cluster
MIRU-VNTR
cluster
2004 2005 2006
No. of MDR
isolates
No. of XDR
isolates
No. of MDR
isolates
No. of XDR
isolates
No. of MDR
isolates
No. of XDR
isolates
E1 – – 2 0 – –
E2 – – 3 0 – –
Lisboa3 18 11 24 18 15 13
Lisboa4 2 1 – – – –
Lisboa10 – – 2 0 – –
Q1 7 3 12 8 6 3
– Not detected in that year.
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associated with XDR-TB [6,7,14]. Monitoring of these strains
through timely genotypic analysis would provide a way to
identify more rapidly MDR-TB and XDR-TB cases and
ensure greater tracing of contacts, with the aim of containing
these strains, thereby avoiding a possible XDR-TB outbreak.
Given the high clonality that was found associated with
MDR-TB and XDR-TB, and because genotyping results can
be obtained earlier than DST results, the identiﬁcation of an
isolate belonging to a MDR-TB or XDR-TB associated clus-
ter might be useful in identifying a possible MDR-TB or
XDR-TB strain at an earlier stage.
Transmission can also be enhanced by another factor, the
sputum smear-positive case rate. Sputum smear-positivity is
associated with higher transmission and Portugal has a high
sputum smear-positive case rate when compared with the
majority of the EU countries, which per se may be predictive
of a worse outcome [15–17]. The explanation for higher
bacillary loads might be related to the strain itself or may be
due to a delayed case detection. If effective measures are
not put in place to avoid the transmission of these strains, it
is conceivable that an increase in the inherently high treat-
ment costs of MDR-TB and XDR-TB for national tuberculo-
sis control programmes may occur, diverting resources that
are necessary to control TB [18].
A limitation of this study is the fact that a convenience
sample was used. Nevertheless, the high number of cases
found within such a reduced geographic region justiﬁes par-
ticular attention and urgent implementation of control mea-
sures.
A study concerning XDR-TB treatment in Tomsk, Russia,
by Keshavjee et al. [3] showed that although there was a less
favorable outcome it was possible to treat XDR-TB with
regimens including ﬁve active drugs plus a ﬂuoroquinolone
and capreomycin even when resistance was found. In the
Portuguese setting, as we have shown, given the higher
degree of resistance, the problem resides in ﬁnding at least
four active drugs. This study is an important contribution to
knowledge concerning drug resistance in Portugal and
improvement of standard treatment regimens.
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